Jim Cramer on Kenvue: “I Think It is a Good Situation, Not a Bad One”

Kenvue Inc. (NYSE:KVUE) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if long-term shareholders should be worried. Here’s what Mad Money’s host had to say in response:

“Okay, it’s a really important question because I’ve been looking to buy Kimberly. I think the answer is no. I think you’ll be fine. There’s going to be lawsuits. We’ve dealt with them before. Look at Johnson & Johnson… I think it is a good situation, not a bad one.”

A person with stock market data on a laptop. Photo by Anna Nekrashevich on Pexels

Kenvue Inc. (NYSE:KVUE) provides consumer health products across pain relief, allergy care, digestive support, wellness, and personal care under its brands. Some of its products include Tylenol, Motrin, Calpol, Neutrogena, and Band-Aid. A caller mentioned the company’s litigation during the September 18 episode, and Cramer responded:

“I don’t think the litigation risk is nearly as bad as people think. This stock is at 4.5%. It’s got new leadership. I don’t want to dump it right here. I just don’t, but I don’t expect a lot of upside here. That’s the problem.”

While we acknowledge the risk and potential of KVUE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KVUE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.